Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression

被引:28
|
作者
Daniels, BA
Kirkby, KC
Hay, DA
Mowry, BJ
Jones, IH
机构
[1] Univ Tasmania, Div Clin Sci, Hobart, Tas 7001, Australia
[2] Curtin Univ Technol, Sch Psychol, Perth, WA 6001, Australia
[3] Wolston Pk Hosp, Brisbane, Qld, Australia
关键词
bipolar disorder; depression; rehospitalisation; schizophrenia;
D O I
10.3109/00048679809062740
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The aim of this study was to examine the rate of rehospitalisation for schizophrenia, bipolar disorder and depression over a 5-year period in Tasmania, and to identify predictors of the number and duration of readmissions. Method: The Tasmanian Mental Health Register was used to study the 5-year pattern of rehospitalisation for all patients admitted to a Tasmanian public psychiatric inpatient facility with a primary diagnosis of schizophrenia, bipolar disorder or depression, in 1983 or 1984. Results: Seventy-one percent of patients receiving a diagnosis of schizophrenia were readmitted in the 5-year period, compared to 59% for bipolar disorder and 48% for depression. For all three diagnoses, the number of prior admissions was a predictor of the number of readmissions and the total number of days spent in hospital in the follow-up period. Age and sex also had significant effects, which varied across diagnostic groups. Conclusions: A substantial proportion of patients hospitalised for schizophrenia, bipolar disorder or schizophrenia were rehospitalised during the next 5 years. Patients with more previous admissions had more readmissions than those with fewer previous admissions.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 50 条
  • [41] Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression
    S H Fatemi
    J A Earle
    T McMenomy
    Molecular Psychiatry, 2000, 5 : 654 - 663
  • [42] Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression
    Fatemi, SH
    Earle, JA
    McMenomy, T
    MOLECULAR PSYCHIATRY, 2000, 5 (06) : 654 - 663
  • [43] Level of Thyroid-Stimulating Hormone (TSH) in Patients with Acute Schizophrenia, Unipolar Depression or Bipolar Disorder
    Wysokinski, Adam
    Kloszewska, Iwona
    NEUROCHEMICAL RESEARCH, 2014, 39 (07) : 1245 - 1253
  • [44] Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder
    Farrow, TFD
    Whitford, TJ
    Williams, LM
    Gomes, L
    Harris, AWF
    BIOLOGICAL PSYCHIATRY, 2005, 58 (09) : 713 - 723
  • [45] Pareidolia in Schizophrenia and Bipolar Disorder
    Abo Hamza, Eid G.
    Keri, Szabolcs
    Csigo, Katalin
    Bedewy, Dalia
    Moustafa, Ahmed A.
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [46] VIOLENCE IN SCHIZOPHRENIA AND BIPOLAR DISORDER
    Volavka, Jan
    PSYCHIATRIA DANUBINA, 2013, 25 (01) : 24 - 33
  • [47] Consanguinity, schizophrenia and bipolar disorder
    Dahdouh-Guermouche, Aicha
    Taleb, Mohammed
    Courtet, Philippe
    Semaoune, Boualem
    Malafosse, Alain
    ANNALES MEDICO-PSYCHOLOGIQUES, 2013, 171 (04): : 246 - 250
  • [48] Neurobiology of schizophrenia and bipolar disorder
    Hans-Jórgen Mφller
    Annals of General Psychiatry, 7 (Suppl 1)
  • [49] Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
    Modugula, Harika
    Kumar, Anoop
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (02) : 109 - 114
  • [50] Medication Profile and Treatment Cost Estimation Among Outpatients with Schizophrenia, Bipolar Disorder, Depression, and Anxiety Disorders in Indonesia
    Puspitasari, Irma M.
    Sinuraya, Rano K.
    Rahayu, Cherry
    Witriani, Witriani
    Zannah, Uzlifatul
    Hafifah, Auliani
    Ningtyas, Ajeng R.
    Vildayanti, Hilda
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 815 - 828